ARTICLE | Clinical News
Bococizumab: Phase III data
July 18, 2016 7:00 AM UTC
Top-line data from the double-blind, international Phase III SPIRE- FH trial in 370 patients with HeFH at high or very high risk of cardiovascular events showed that 150 mg subcutaneous bococizumab ev...